About Us: Who We Are

We are a healthcare company focused on the development and marketing of novel cellular and molecular diagnostic risk assessment products for breast cancer.

Using our patented, FDA-cleared MASCT System, a nurse or physician’s assistant, can painlessly collect a sample of Nipple Aspirate Fluid (NAF) in about 10 minutes. The MASCT device is intended for use in the collection of nipple aspirate fluid for cytological testing. The collected fluid can be used in the determination and/or differentiation of normal versus premalignant versus malignant cells.

Our name comes from Atossa, daughter of Cyrus the Great and wife of Darius I, the King of the Achaemenid Empire. In about 470 BC she became the first woman in recorded history to be diagnosed with breast cancer.